June 19th 2025
Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.
Nina Chavez: OCM Has Made Community Oncologists Better Business People
Dr Blase Polite Outlines the Decision to Move to 2-Sided Risk in the OCM
Dr James Hamrick Discusses Bringing Value to Patients Through Engagement
Lessons From the Field: How Practices Are Succeeding Under OCM
Mike Fazio: Practices Are Happier With PP4 Results in the OCM